1. Home
  2. DGICB vs ESPR Comparison

DGICB vs ESPR Comparison

Compare DGICB & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DGICB

Donegal Group Inc. Class B

N/A

Current Price

$19.13

Market Cap

654.6M

Sector

Finance

ML Signal

N/A

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGICB
ESPR
Founded
1986
2008
Country
United States
United States
Employees
851
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
654.6M
731.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
DGICB
ESPR
Price
$19.13
$3.13
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.75
AVG Volume (30 Days)
416.0
17.2M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
3.34%
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
$2.26
N/A
Revenue Next Year
N/A
$12.81
P/E Ratio
$8.06
N/A
Revenue Growth
N/A
21.31
52 Week Low
$13.84
$0.76
52 Week High
$20.30
$4.18

Technical Indicators

Market Signals
Indicator
DGICB
ESPR
Relative Strength Index (RSI) 54.00 70.78
Support Level $15.57 $2.37
Resistance Level $19.72 $3.15
Average True Range (ATR) 0.42 0.03
MACD -0.10 0.04
Stochastic Oscillator 75.11 96.12

Price Performance

Historical Comparison
DGICB
ESPR

About DGICB Donegal Group Inc. Class B

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: